IntraBio Expands Niemann-Pick Trial to ID Neuroprotective, Disease-Modifying Effects

IntraBio Expands Niemann-Pick Trial to ID Neuroprotective, Disease-Modifying Effects

Source: 
BioSpace
snippet: 

IntraBio lauched a Phase II expansion study for IB1001 (N-Acetyl-L-Leucine) soon after announcing positive results from the initial “parent” multinational trials for Niemann-Pick disease Type C (NPC). The expansion study is designed to assess the neuroprotective, disease-modifying effects of the drug. The company plans to approach the FDA in the next few weeks in hopes of gaining approval for the drug based on the relief of symptoms demonstrated in the initial “parent” study.